API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: BB2603
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
MOB-015 (terbinafine) is an in-house developed topical formulation, which is investigated for the treatment of onychomycosis and Topline results are expected in January 2025.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Padagis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2022
Details:
With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.
Lead Product(s): Terbinafine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020